Integra Lifesciences Holdings (IART) Receivables - Net (2009 - 2026)

Integra Lifesciences Holdings' Receivables - Net history runs 18 years deep, the most recent figure standing at $264.4 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 4.74% year-over-year to $264.4 million; the TTM figure through Mar 2026 stood at $264.4 million (up 4.74% YoY), while the FY2025 annual figure was $278.8 million, up 2.38% from the prior year.
• Receivables - Net came in at $264.4 million for Q1 2026 at Integra Lifesciences Holdings, down from $278.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $284.5 million in Q2 2025 to a low of $234.0 million in Q1 2022.
• A 5-year average of $258.0 million and a median of $258.7 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net climbed 13.65% in 2022 and declined 5.08% in 2024, its largest moves.
• Integra Lifesciences Holdings' Receivables - Net stood at $263.5 million in 2022, then decreased by 1.57% to $259.3 million in 2023, then increased by 5.03% to $272.4 million in 2024, then climbed by 2.38% to $278.8 million in 2025, then slipped by 5.18% to $264.4 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $264.4 million, $278.8 million, and $262.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison